文献速递白血病

CD7表达在野生型或突变型CEBPA急性髓系白血病中的预后意义

[CD7 expression and its prognostic significance in acute myeloid leukemia patients with wild-type or mutant CEBPA].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2020-01-01

该回顾性研究分析298例初治非M3急性髓系白血病(AML)患者,发现CD7(+)组CEBPA单位点和双位点突变率分别为10.1%和33.9%,显著高于CD7(-)组的5.3%和4.2%(P=0.000)。CD7(+)在CEBPA野生型与突变型AML中预后意义相反,据此建立的危险分层模型3年OS率分别为80.2%、48.0%和30.6%(P<0.001)。

要点

  • CD7(+)组CEBPA突变率显著高于CD7(-)组(P=0.000)。
  • CEBPA野生型中CD7(+)组完全缓解率低、复发率高。
  • CEBPA突变型中CD7(+)组总生存和无病生存更优。

核心结论

  • CD7(+)组中CEBPA突变率显著高于CD7(-)组。
  • CD7(+)在CEBPA野生型组和突变组AML中存在截然相反的预后意义。
  • 根据CD7表达和CEBPA突变建立的新危险分层模型有助于指导临床个体化治疗。

研究设计与样本

  • 回顾性分析2010年1月至2016年12月收治的298例初治AML患者(除外M3亚型)的临床资料。
  • 在全部患者以及CEBPA野生型和突变型组中,分别比较CD7(+)和CD7(-)患者的临床特征及预后差异。

主要发现

  • CD7(+)组CEBPA单位点和双位点突变率分别为10.1%和33.9%,显著高于CD7(-)组的5.3%和4.2%(P=0.000)。
  • CEBPA野生型患者中,CD7(+)组较CD7(-)组完全缓解率低(P=0.001)、复发率高(P=0.023),两组OS和DFS差异无统计学意义(P值均>0.05)。
  • CEBPA突变患者中,CD7(+)组显示更长的OS(P=0.019)和DFS(P=0.010)。
  • 三组(CD7(+)伴CEBPA突变组、CD7(-)组、CD7(+)伴CEBPA野生型组)3年OS率分别为80.2%、48.0%和30.6%(P<0.001),3年DFS率分别为74.1%、37.4%和22.2%(P<0.001)。

临床怎么用

  • 对初治非M3 AML患者可联合检测CD7表达与CEBPA突变状态进行危险分层。
  • CD7(+)伴CEBPA突变者预后较好,CD7(+)伴CEBPA野生型者预后较差。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To analyze the prognostic value of CD7 expression in newly diagnosed acute myeloid leukemia (AML) patients, and to further explore the correlation between CD7 expression and CEBPA mutation, and to clarify the prognostic value of CD7(+) in AML patients with wild-type (WT) or mutant-type (MT) CEBPA. Methods: The clinical data of 298 newly diagnosed non-M(3) AML patients between January 2010 and December 2016 were analyzed retrospectively. The clinical characteristics and prognosis of CD7(+) and CD7(-) patients were respectively compared in all patients, and in patients with WT and MT CEBPA. The relationship between CD7 expression and CEBPA mutation was determined by chi-square, and the effects of CEBPA mutation on survival and prognosis in CD7(+) group by Kaplan-Meier method. Results: In CD7(+) group, the frequencies of CEBPA mutation were 10.1% (single site) and 33.9% (double site) , significantly higher than those of the CD7(-) group (5.3% and 4.2%) (P=0.000) . Subgroup prognostic analysis showed a lower CR rate (P=0.001) and a higher RR (P=0.023) in CD7(+) group comparing to those of CD7(-) group in AML patients with wild type CEBPA. There were no statistical difference between CD7(+) group and CD7(-) group in overall survival (OS) and disease free survival (P>0.05) , while in the CEBPA mutant group the CD7(+) group has higher OS (P=0.019) and DFS (P=0.010) . Based on the CD7 expression and CEBPA mutation, 298 cases were divided into 3 subgroups, named as CD7(+)-CEBPA MT group, CD7(-) and CD7(+)-CEBPA WT group. The 3-year OS of the 3 groups were 80.2%, 48.0% and 30.6%, respectively (P<0.001) , and the 3-year DFS were 74.1%, 37.4% and 22.2%, respectively (P<0.001) . Conclusion: The CEBPA mutation rate was higher in CD7(+) AML patients then that of CD7(-) patients. CD7 expression has opposite prognostic significance in AML patients carrying the wild-type or mutant-type CEBPA. Based on CD7 expression and CEBPA mutation, a new risk stratification model can be established, which is helpful to guide the clinical individualized treatment for AML patients. 目的: 分析CD7在初治急性髓系白血病(AML)患者中的表达和预后价值,进一步探讨CD7表达情况与CEBPA突变的相关性,明确其在CEBPA野生型和突变型AML患者中与预后的关系。 方法: 回顾性分析2010年1月至2016年12月收治的298例初治AML患者(除外M(3)亚型)的临床资料,在全部患者以及CEBPA野生型和突变型组中,分别比较CD7阳性(CD7(+))和CD7阴性(CD7(-))患者的临床特征及预后差异,并联合CD7表达情况和CEBPA突变状态初步建立新的危险分层模型。 结果: 在CD7(+)组中,CEBPA单位点和双位点突变的发生率分别为10.1%和33.9%,显著高于CD7(-)组(5.3%和4.2%),差异具有统计学意义(P=0.000)。在CEBPA野生型患者中,CD7(+)组患者相较CD7(-)组患者完全缓解率低(P=0.001)、复发率高(P=0.023),而两组总生存(OS)期和无病生存(DFS)期差异无统计学意义(P值均>0.05);在CEBPA突变患者中,CD7(+)组显示有更长的OS期(P=0.019)和DFS期(P=0.010)。根据CD7表达和CEBPA突变与否将AML患者分为三个亚组:CD7(+)伴CEBPA突变组、CD7(-)组和CD7(+)伴CEBPA野生型组。三组患者的3年OS率分别为80.2%、48.0%和30.6%(P<0.001),3年的DFS率分别为74.1%、37.4%和22.2%(P<0.001)。 结论: CD7(+)组中CEBPA突变率显著高于CD7(-)组,CD7(+)在CEBPA野生型组和突变组AML中存在截然相反的预后意义。根据CD7表达情况和CEBPA突变与否建立新的危险分层模型,有助于指导临床个体化治疗。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Zhu MY, Zhu Y, Chen RR, et al. [CD7 expression and its prognostic significance in acute myeloid leukemia patients with wild-type or mutant CEBPA]. Zhonghua Xue Ye Xue Za Zhi. 2020. PMID: 32135624. doi:10.3760/cma.j.issn.0253-2727.2020.02.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。